Related Experiment Video
Updated: Jul 4, 2026
07:25
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Novel therapies in hepatitis B and C
Bart Takkenberg1, Joep de Bruijne, Christine Weegink
1Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
Current Gastroenterology Reports
|April 18, 2008
Summary
New hepatitis B and C treatments are emerging. This review covers promising new drugs for chronic hepatitis B and C, offering hope for better disease management and improved patient outcomes.
Area of Science:
- Hepatology and Viral Gastroenterology
- Pharmacology and Drug Development
Background:
- Chronic hepatitis B and C impact 500 million globally, causing liver cirrhosis and cancer.
- Current treatments for chronic hepatitis B have limited efficacy and side effects.
- Hepatitis C virus (HCV) research has advanced understanding of its life cycle, facilitating rapid therapeutic development.
Purpose of the Study:
- To review emerging and novel therapeutic agents for chronic hepatitis B.
- To summarize advancements in treatment strategies for chronic hepatitis C.
- To provide an overview of the most significant new drugs for viral hepatitis.
Main Methods:
- Literature review of recent scientific publications.
- Analysis of clinical trial data for new antiviral agents.
- Synthesis of information on drug mechanisms and efficacy.
Main Results:
- Several promising new drugs for chronic hepatitis B are nearing approval but require further research.
- Rapid progress in understanding the HCV life cycle has accelerated the development of new hepatitis C therapies.
- The review identifies key emerging agents with potential to improve treatment outcomes.
Conclusions:
- Novel therapeutic agents offer improved prospects for managing chronic hepatitis B and C.
- Continued research and development are crucial for optimizing antiviral therapies.
- Emerging treatments represent a significant step forward in addressing the global burden of viral hepatitis.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...